查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
原發性免疫力缺乏治療市場規模、佔有率和成長分析（按適應症、藥物類別、給藥途徑、年齡層、分銷管道和地區分類）—產業預測（2026-2033 年）
市場調查報告書
商品編碼
1900581

原發性免疫力缺乏治療市場規模、佔有率和成長分析（按適應症、藥物類別、給藥途徑、年齡層、分銷管道和地區分類）—產業預測（2026-2033 年）

Primary Immunodeficiency Therapeutics Market Size, Share, and Growth Analysis, By Indication, By Drug Class, By Route of Administration, By Age Group, By Distribution Channel, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 186 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球原發性免疫力缺乏疾病治療市場預計到 2024 年將達到 29.6 億美元，到 2025 年將達到 31.3 億美元，到 2033 年將達到 48.7 億美元，預測期（2026-2033 年）的複合年成長率為 5.7%。

全球原發性免疫力缺乏（PI）治療市場正穩步成長，這主要得益於公眾意識的提高、診斷技術的進步以及個人化治療方法的廣泛應用。原發性免疫力缺乏涵蓋約450種罕見慢性疾病，這些疾病是由影響免疫系統抵抗感染能力的基因缺陷所引起。基因技術的進步和先進的篩檢方法使得早期診斷成為可能，從而推動了對免疫球蛋白替代療法、生物目標和造血幹細胞移植等長期治療的需求。北美和歐洲的監管機構日益關注罕見疾病藥物的研發，促使對新型治療方法的投資不斷增加。此外，患者權益倡導組織和官民合作關係的共同努力正在改善治療的可及性和醫療質量，尤其是在新興市場。

推動全球原發性免疫力缺乏治療市場發展的因素

近年來，診斷技術的創新，包括次世代定序和基因篩檢，顯著縮短了原發性免疫力缺乏疾病（PI）的診斷時間。快速診斷使得治療能夠更早啟動，進而減少感染疾病相關併發症，改善治療效果。診斷準確性的提高有助於有效管理PI，增強患者的治療依從性，並最終改善患者的整體生活品質。技術和患者照護的這些進步正在推動對原發性免疫力缺乏疾病治療的需求成長，並促進全球相關療法市場的發展。

限制全球原發性免疫力缺乏治療市場發展的因素

全球原發性免疫力缺乏治療市場面臨的一大挑戰是免疫球蛋白、基因療法和幹細胞療法的高成本。這些成本限制了治療的可及性，尤其是在低收入國家，並限制了患者獲得這些至關重要且可能挽救生命的治療的機會。此外，血漿採整合本的不斷上漲也推高了免疫球蛋白療法的整體成本，這一趨勢同樣影響已開發國家。這些經濟障礙往往導致保險報銷困難，阻礙了患者獲得治療，並增加了醫療系統有效建立和維持長期治療計畫的能力。

全球原發性免疫力缺乏治療藥物市場趨勢

全球原發性免疫力缺乏治療市場正經歷人工智慧（AI）融入治療通訊協定的顯著趨勢，尤其是在個人化免疫球蛋白給藥方面。 AI驅動的給藥演算法透過基於患者體重、感染頻率和代謝率等關鍵因素制定個人化治療方案，正在變革患者照護。這項創新不僅提高了治療依從性，還最大限度地降低了給藥不足和過量的風險，從而最佳化了資源利用。正在進行的臨床檢驗正在驗證AI在不同患者群體中的有效性，進一步加速了原發性免疫力缺乏領域精準醫療的發展。這反映了整個行業向個人化醫療解決方案的轉變。

目錄

介紹

  • 調查目標
  • 調查範圍
  • 定義

調查方法

  • 資訊收集
  • 二手資料和一手資料方法
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 全球市場展望
  • 供需趨勢分析
  • 細分市場機會分析

市場動態與展望

  • 市場規模
  • 市場動態
    • 促進因素和機遇
    • 限制與挑戰
  • 波特分析

關鍵市場考察

  • 關鍵成功因素
  • 競爭程度
  • 關鍵投資機會
  • 市場生態系統
  • 市場吸引力指數（2025）
  • PESTEL 分析
  • 總體經濟指標
  • 價值鏈分析
  • 定價分析

全球原發性免疫力缺乏缺陷疾病治療市場規模（按適應症和複合年成長率分類）（2026-2033 年）

  • 通用變異型免疫力缺乏症（CVID）
  • X連鎖無丙種球蛋白血症（XLA）
  • 重症聯合免疫力缺乏症（SCID）
  • 威斯科特-奧爾德里奇症候群（WAS）
  • 高IgM症候群（HIGM）

全球原發性免疫力缺乏治療藥物市場規模（按藥物類別分類）及複合年成長率（2026-2033 年）

  • 免疫球蛋白替代療法
  • 免疫調節劑
  • 幹細胞療法
  • 基因治療
  • 抗生素

全球原發性免疫力缺乏治療藥物市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

  • 靜脈注射（IV）
  • 皮下（SC）
  • 肌肉內注射（IM）

全球原發性免疫力缺乏治療市場規模（按年齡層分類）及複合年成長率（2026-2033 年）

  • 兒童
  • 成人

全球原發性免疫力缺乏治療藥物市場規模（按分銷管道分類）及複合年成長率（2026-2033 年）

  • 醫院
  • 專科藥房
  • 網路藥房

全球原發性免疫力缺乏治療藥物市場規模及複合年成長率（2026-2033）

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲地區

競爭資訊

  • 前五大公司對比
  • 主要企業的市場定位（2025 年）
  • 主要市場參與者所採取的策略
  • 近期市場趨勢
  • 公司市佔率分析（2025 年）
  • 主要企業公司簡介
    • 公司詳情
    • 產品系列分析
    • 依業務板塊進行公司股票分析
    • 2023-2025年營收年比比較

主要企業簡介

  • CSL Behring（USA）
  • Grifols（Spain）
  • Octapharma（Switzerland）
  • Takeda Pharmaceutical Company Limited（Japan）
  • Biotest AG（Germany）
  • ADMA Biologics（USA）
  • Bio Products Laboratory（BPL）（USA）
  • LFB SA（France）
  • Kedrion Biopharma SpA（Italy）
  • Pfizer Inc.（USA）
  • Orchard Therapeutics（UK）
  • Rocket Pharmaceuticals（USA）
  • Bluebird Bio（USA）
  • China Biologic Products Holdings（China）
  • GC Pharma（South Korea）
  • Baxter International Inc.（USA）
  • X4 Pharmaceuticals（USA）
  • Novartis AG（Switzerland）
  • Sanofi SA（France）
  • Bristol Myers Squibb（USA）

結論與建議

簡介目錄
Product Code: SQMIG35D2303

Global Primary Immunodeficiency Therapeutics Market size was valued at USD 2.96 Billion in 2024 and is poised to grow from USD 3.13 Billion in 2025 to USD 4.87 Billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

The global primary immunodeficiency (PI) therapeutics market is witnessing steady growth, driven by increased awareness, improved diagnostic techniques, and the availability of tailored treatment options. With around 450 rare, chronic disorders categorized under primary immunodeficiencies, these conditions stem from genetic defects impacting the immune system's ability to fight infections. Advances in genetic technology and enhanced screening methods facilitate early diagnosis, boosting the demand for long-term treatments such as immunoglobulin replacement therapy, targeted biologics, and hematopoietic stem cell transplantation. Regulatory bodies in North America and Europe have shown increasing interest in orphan drug development, leading to more investment in novel therapies. Moreover, concerted efforts by patient advocacy groups and public-private partnerships are improving accessibility and care, particularly in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Primary Immunodeficiency Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Primary Immunodeficiency Therapeutics Market Segments Analysis

Global Primary Immunodeficiency Therapeutics Market is segmented by Indication, Drug Class, Route of Administration, Age Group, Distribution Channel and region. Based on Indication, the market is segmented into Common Variable Immunodeficiency (CVID), X-linked Agammaglobulinemia (XLA), Severe Combined Immunodeficiency Disorders (SCID), Wiskott-Aldrich Syndrome (WAS) and Hyper-IgM Syndrome (HIGM). Based on Drug Class, the market is segmented into Immunoglobulin Replacement Therapy, Immune-modulating Agents, Stem Cell Therapy, Gene Therapy and Antibiotics. Based on Route of Administration, the market is segmented into Intravenous (IV), Subcutaneous (SC) and Intramuscular (IM). Based on Age Group, the market is segmented into Pediatric and Adult. Based on Distribution Channel, the market is segmented into Hospitals, Specialty Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Primary Immunodeficiency Therapeutics Market

Recent innovations in diagnostic technology, including next-generation sequencing and genetic screening, have significantly reduced the time needed to diagnose primary immunodeficiency (PI) diseases. Swift diagnosis enables the prompt commencement of treatment, which in turn leads to improved therapeutic outcomes by lessening infection-related complications. Enhanced diagnostic accuracy contributes to more effective management of PI, fosters better patient adherence to treatment, and ultimately improves overall quality of life for those affected. This progression in both technology and patient care has led to a growing demand for primary immunodeficiency medications, propelling the expansion of the global market for these therapeutics.

Restraints in the Global Primary Immunodeficiency Therapeutics Market

A significant challenge facing the global primary immunodeficiency therapeutics market is the high cost associated with immunoglobulin therapy, gene therapy, and stem cell therapy. Such expenses create affordability issues, particularly in low-income countries, restricting patient access to essential treatments that could be life-saving. In addition, the rising prices of plasma collection further contribute to the overall cost of immunoglobulin treatments, a trend that is also affecting developed nations. These financial obstacles often lead to reimbursement difficulties, hindering patient access and complicating the ability of healthcare systems to establish and sustain long-term treatment programs effectively.

Market Trends of the Global Primary Immunodeficiency Therapeutics Market

The Global Primary Immunodeficiency Therapeutics market is witnessing a significant trend towards the integration of artificial intelligence in treatment protocols, particularly through individualized immunoglobulin dosing. AI-driven dose algorithms are transforming patient care by personalizing treatment regimens based on key factors like patient weight, infection frequency, and metabolic rates. This innovation not only enhances treatment adherence but also minimizes the risks of under- or overdosing, thereby optimizing resource utilization. As ongoing clinical trials seek to validate AI efficacy across diverse patient populations, the momentum for precision medicine in primary immunodeficiency is expected to gain traction, reflecting a broader industry shift towards tailored healthcare solutions.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Primary Immunodeficiency Therapeutics Market Size by ndication & CAGR (2026-2033)

  • Market Overview
  • Common Variable Immunodeficiency (CVID)
  • X-linked Agammaglobulinemia (XLA)
  • Severe Combined Immunodeficiency Disorders (SCID)
  • Wiskott-Aldrich Syndrome (WAS)
  • Hyper-IgM Syndrome (HIGM)

Global Primary Immunodeficiency Therapeutics Market Size by Drug Class & CAGR (2026-2033)

  • Market Overview
  • Immunoglobulin Replacement Therapy
  • Immune-modulating Agents
  • Stem Cell Therapy
  • Gene Therapy
  • Antibiotics

Global Primary Immunodeficiency Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Intravenous (IV)
  • Subcutaneous (SC)
  • Intramuscular (IM)

Global Primary Immunodeficiency Therapeutics Market Size by Age Group & CAGR (2026-2033)

  • Market Overview
  • Pediatric
  • Adult

Global Primary Immunodeficiency Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Specialty Pharmacies
  • Online Pharmacies

Global Primary Immunodeficiency Therapeutics Market Size & CAGR (2026-2033)

  • North America (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • US
    • Canada
  • Europe (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • CSL Behring (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Grifols (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Octapharma (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biotest AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ADMA Biologics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio Products Laboratory (BPL) (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LFB SA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kedrion Biopharma S.p.A. (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Orchard Therapeutics (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Rocket Pharmaceuticals (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bluebird Bio (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • China Biologic Products Holdings (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GC Pharma (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • X4 Pharmaceuticals (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations